osimertinib
astrazeneca
['adaura', 'lcsm,(-blcsm)', 'clear result']
adaura; dfs hr 0.23 in ii/iiia; dfs 0.27 inc ib; nice hr by stage: compelling cns dfs and neuro protection: 9% qtc prolongation. soc. clear result. await os. #esmo22 #lcsm 
Consultant Medical Oncologist, UK. Views are hypothesis generating discourse. Post COVID dabbling in garden.